NY-IFF
19.3.2024 11:46:34 CET | Business Wire | Press release
IFF (NYSE: IFF) today announced that it has entered into a definitive agreement to sell its Pharma Solutions business unit to French leader of plant-based ingredients Roquette for an enterprise value of up to $2.85 billion, which represents an enterprise value to EBITDA multiple of approximately 13x. IFF’s Pharma Solutions business is a well-established developer and manufacturer of pharmaceutical excipients and includes its Global Specialty Solutions business supporting industrial and methyl cellulosic food applications. The Pharma Solutions business being sold to Roquette is primarily made up of businesses within IFF’s existing Pharma Solutions division, with some adjustments to the perimeter of the transaction designed to align customers, businesses and the manufacturing footprint.
“We are pleased to reach an agreement with Roquette that will support Pharma Solutions’ next chapter of growth as a trusted partner for the pharmaceutical industry,” said IFF CEO Erik Fyrwald. "An important next step in our portfolio optimization strategy, the sale of Pharma Solutions, along with other recent actions such as our dividend rightsizing, represents a significant step towards our commitment to reducing debt leverage to 3.0x or below. This also enables us to increase focus on the core drivers of long-term profitable growth and maximize value for our shareholders. We are grateful for the many contributions of our Pharma colleagues and are confident that with Roquette, the Pharma Solutions business will be well positioned to expand its industry leadership through continued investment in innovation to meet the evolving needs of pharmaceutical manufacturers and developers worldwide.”
"We are excited to enter into this partnership with the talented Pharma Solutions team at IFF, which has grown into the go-to partner in the pharmaceutical excipients and specialty solutions markets globally,” said Pierre Courduroux, CEO of Roquette. “The combination of our excipients expertise with IFF Pharma is a fantastic opportunity to become a true global specialist of drug delivery and oral dosage solutions, responding to the needs of our customers and to the demands of patients who are looking for continuously better treatments.”
Pharma Solutions operates 10 research and development and/or production sites globally, with approximately 1100 employees, and generated approximately $1B revenue in 2023. IFF and Roquette expect to close the transaction in the first half of 2025, subject to applicable information and/or consultation requirements and customary closing conditions, including regulatory approvals. J.P. Morgan Securities LLC acted as exclusive financial advisor to IFF, Skadden, Arps, Slate, Meagher & Flom LLP acted as counsel, and Evercore as advisor to the board.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318143532/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H55 Delivers Certification-Grade Propulsion Battery Modules to Pratt & Whitney Canada, Supporting Demonstration of Hybrid-Electric Aircraft Technology9.6.2026 17:31:00 CEST | Press release
Production-conforming systems manufactured in a regulator-approved facility mark H55’s transition from technology development to commercialization of certification-grade energy storage solutions for hybrid-electric aviation. H55 today announced the delivery of certification-grade propulsion battery modules to Pratt & Whitney Canada in support of the RTX Hybrid-Electric Flight Demonstrator — a milestone that further validates H55’s transition from technology development to industrial-scale execution and represents an important step in the commercialization of the company’s certification-grade energy storage technologies for hybrid-electric aerospace applications. Pratt & Whitney is an RTX business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609825006/en/ H55 Adagio Battery Modules in Pratt & Whitney Canada Hangar ©RTX The delivery represents more than hardware integration. It demonstrates H55’s ability to manufacture p
New Polymorph of Indomethacin Discovered9.6.2026 17:00:00 CEST | Press release
- Joint Research Involving Rigaku Published in Crystal Growth & Design - Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced that the results of a joint research project conducted with Shionogi & Co., Ltd., JEOL Ltd., and Meiji Pharmaceutical University have been published in Crystal Growth & Design, a world-renowned international journal in the field of crystallography. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609347405/en/ Cover of the June 2026 issue of Crystal Growth & Design, featuring this research. This research uncovered a previously unknown polymorph (κ-form) of indomethacin, a widely used pain relief and anti-inflammatory drug. The research team also conducted structural analysis and characterization of the newly identified crystal form. Although indomethacin has
SLB Collaborates with Qualcomm on Edge AI Solutions for Energy Operations9.6.2026 16:28:00 CEST | Press release
Collaboration combines edge computing and energy workflows to support real-time operational decision-making Global energy technology company SLB (NYSE: SLB) today announced a memorandum of understanding with Qualcomm Technologies, Inc. to enable edge AI solutions for the energy industry, supporting real-time operational decision-making across wells, facilities and production systems. The collaboration combines Qualcomm Technologies’ low-power edge computing and AI processing capabilities, with SLB’s Agora™ edge AI and IoT solutions developed for remote and operationally complex environments. “Together, SLB and Qualcomm Technologies aim to help operators apply AI more effectively across energy infrastructure,” said Rakesh Jaggi, president, Digital, SLB. “Many energy operations rely on real-time decision-making in remote environments where connectivity and responsiveness directly affect performance. AI systems designed around the realities of energy operations can help support more consi
RevBits and Stony Brook University’s Ethos Lab Establish a Collaborative Partnership to Further the Field of Cyber Security Education and Application9.6.2026 16:15:00 CEST | Press release
Through the partnership, RevBits will provide its full suite of cybersecurity solutions to Stony Brook University’s Ethos Lab, to deliver the capability to advance student education and equip them with the knowledge needed to face modern cyber threats in a realistic, contained environment. Stony Brook University’s (SBU) Ethos Lab, in the College of Engineering and Applied Sciences Department of Computer Science, recently announced a collaborative partnership with RevBits, LLC. Through the partnership, SBU’s Ethos Lab will utilize the RevBits solutions suite to build computer science labs and a cybersecurity-focused curriculum, reinforcing lessons from the classroom. The platform simulates environments containing five major threat landscapes, including Endpoint Security, Privileged Access Management, Email Security, Zero Trust Network and Deception Technology. SBU’s Department of Computer Science was recently designated as a National Center of Academic Excellence in Cybersecurity Resear
Marie® by Leo Cancer Care Makes History at Stanford Medicine — World First in Compact Upright Proton Therapy9.6.2026 15:22:00 CEST | Press release
The first patient treated was a child. The milestone marks the moment upright proton therapy moves from innovation to adoption — and reflects exactly what Leo Cancer Care built Marie® to achieve Following the landmark first treatment at Stanford Medicine Cancer Center Care June 4, Leo Cancer Care today announces the role of its Marie® upright patient positioning and imaging platform in enabling the world's first compact upright proton therapy patient treatment. Delivered using the Mevion S250-FIT™ Proton Therapy System and powered by RayStation from RaySearch, the milestone is the culmination of a decade of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609870736/en/ The treatment room at Stanford Medicine Cancer Center, Palo Alto, California, housing the Marie® upright patient positioning platform by Leo Cancer Care (center foreground) integrated with the Mevion S250-FIT™ Proton Therapy System. The circular
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom